{"generic":"Levonorgestrel","drugs":["Levonorgestrel","Liletta","Mirena","My Way","Next Choice","Plan B","Plan B One-Step","Skyla"],"mono":{"0":{"id":"337200-s-0","title":"Generic Names","mono":"Levonorgestrel"},"1":{"id":"337200-s-1","title":"Dosing and Indications","sub":{"0":{"id":"337200-s-1-4","title":"Adult Dosing","mono":"<ul><li>The 1-dose regimen of levonorgestrel oral tablets (Plan B(R) One-Step) is available over-the-counter for patients of any age.<\/li><li>The 2-dose regimen of levonorgestrel oral tablets (Plan B(R)) is available over-the-counter for patients 17 years or older<\/li><li><b>Contraception, Female:<\/b> Liletta(TM): Wait at least 6 weeks following childbirth or a second-trimester abortion or miscarriage; otherwise can insert at any time; alternative contraception may be necessary for first 7 days; replace after 3 years<\/li><li><b>Contraception, Female:<\/b> Mirena(R): Insert within 7 days of the onset of menstruation or immediately after first-trimester abortion; replace after 5 years<\/li><li><b>Contraception, Female:<\/b> Skyla(TM): Insert within 7 days of the onset of menstruation or immediately after first-trimester abortion; replace after 3 years<\/li><li><b>Emergency contraception - Postcoital contraception:<\/b> Plan B(R), 1 tablet (0.75 mg) ORALLY as soon as possible within 72 hours after unprotected intercourse, followed by 1 tablet (0.75 mg) ORALLY 12 hours after the first dose<\/li><li><b>Emergency contraception - Postcoital contraception:<\/b> Plan B(R) One-Step, 1 tablet (1.5 mg) ORALLY as soon as possible within 72 hours after unprotected intercourse<\/li><li><b>Endometrial hyperplasia:<\/b> 20 mcg levonorgestrel\/24 hours intrauterine device retained for 6 months  OR for 1 to 5 years or until disease progression (study dosing)<\/li><li><b>Menorrhagia:<\/b> Mirena(R) intrauterine system: healthcare practitioner should insert the system with provided inserter into the uterine cavity within 7 days of the onset of menstruation or immediately after first-trimester abortion; replace after 5 years<\/li><\/ul>"},"1":{"id":"337200-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Use of the levonorgestrel-releasing intrauterine systems or levonorgestrel oral tablets (Plan B(R) or Plan B(R) One-Step) before menarche not indicated<\/li><li>The 1-dose regimen of levonorgestrel oral tablets (Plan B(R) One-Step) is available over-the-counter for patients of any age.<\/li><li>A prescription is required to obtain the 2-dose regimen of levonorgestrel oral tablets (Plan B(R)) for women younger than 17 years<\/li><li><b>Contraception, Female:<\/b> Liletta(TM), 16 years or older: Wait at least 6 weeks following childbirth or a second-trimester abortion or miscarriage; otherwise can insert at any time; alternative contraception may be necessary for first 7 days; replace after 3 years<\/li><li><b>Emergency contraception - Postcoital contraception:<\/b> Plan B(R), after menarche, 1 tablet (0.75 mg) ORALLY as soon as possible within 72 hours after unprotected intercourse, followed by 1 tablet (0.75 mg) ORALLY 12 hours after the first dose<\/li><li><b>Emergency contraception - Postcoital contraception:<\/b> Plan B(R) One-Step, after menarche, 1 tablet (1.5 mg) ORALLY as soon as possible within 72 hours after unprotected intercourse<\/li><\/ul>"},"3":{"id":"337200-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Contraception, Female<\/li><li>Emergency contraception - Postcoital contraception<\/li><li>Menorrhagia<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Endometrial hyperplasia<\/li><li>Endometrial hyperplasia; Prophylaxis - Tamoxifen adverse reaction; Prophylaxis<\/li><li>Endometriosis<\/li><li>Menopausal symptom<\/li><\/ul>"}}},"3":{"id":"337200-s-3","title":"Contraindications\/Warnings","sub":[{"id":"337200-s-3-9","title":"Contraindications","mono":"<ul><li>Acute liver disease or liver tumor (benign or malignant) (intrauterine only)<\/li><li>Acute or history of pelvic inflammatory disease, unless there has been a subsequent intrauterine pregnancy (intrauterine only)<\/li><li>Breast carcinoma, known or suspected, current or history of (intrauterine only)<\/li><li>Conditions associated with increased susceptibility to infections (eg, leukemia, AIDS, IV drug abuse), including pelvic infection (intrauterine only)<\/li><li>Congenital or acquired uterine anomaly, including fibroids, that distorts the uterine cavity (intrauterine only)<\/li><li>Genital bleeding of unknown etiology (intrauterine only)<\/li><li>Hypersensitivity to any component of the product<\/li><li>Intrauterine device that has not been removed (intrauterine only)<\/li><li>Known or suspected progestin-sensitive cancer, current or history of (intrauterine only)<\/li><li>Known or suspected uterine or cervical neoplasia, or unresolved, abnormal Pap smear (intrauterine only)<\/li><li>Postpartum endometriosis or infected abortion in the past 3 months (intrauterine only)<\/li><li>Pregnancy, known or suspected<\/li><li>Untreated cervicitis or vaginitis, including bacterial vaginosis or other lower genital-tract infections, until infection is controlled (intrauterine only)<\/li><li>Use as post-coital (emergency) contraception (intrauterine only)<\/li><li>Uterine bleeding of unknown etiology (intrauterine only)<\/li><\/ul>"},{"id":"337200-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- Marked increase of blood pressure  and if arises, removal may be necessary (intrauterine only)<\/li><li>-- Severe arterial disease, such as stroke or myocardial infarction  and if arises, removal may be necessary (intrauterine only)<\/li><li>-- Heart disease, valvular or congenital, or surgically constructed systemic-pulmonary shunts; increased risk of infective endocarditis with use of intrauterine devices; prophylactic antibiotic therapy at insertion and removal is recommended (intrauterine only)<\/li><li>Endocrine and Metabolic:<\/li><li>-- Diabetes may occur; monitoring recommended in diabetic patients (intrauterine only)<\/li><li>Hematologic:<\/li><li>-- Coagulopathy or concomitant anticoagulant therapy; removal may be necessary (intrauterine only)<\/li><li>Hepatic:<\/li><li>-- Jaundice; if arises, removal may be necessary (intrauterine only)<\/li><li>Immunologic:<\/li><li>-- Sepsis, including Group A streptococcal, has been reported (intrauterine only)<\/li><li>-- Severe infection has been reported (intrauterine only)<\/li><li>Neurologic:<\/li><li>-- Migraine, focal migraine with asymmetrical visual loss or other symptoms indicating transient cerebral ischemia; removal may be necessary (intrauterine only)<\/li><li>-- Severe headache; removal may be necessary (intrauterine only)<\/li><li>Reproductive:<\/li><li>-- Ectopic pregnancy may occur; remove device with occurrence<\/li><li>-- Septic abortion, including septicemia, septic shock, and death, may occur if patient becomes pregnant with intrauterine device in place (intrauterine only); hospitalization and IV antibiotic treatment may be necessary<\/li><li>-- Increased risk of miscarriage, sepsis, premature labor, and premature delivery in patients who become pregnant and intrauterine device cannot or is chosen to not be removed; monitoring recommended (intrauterine only)<\/li><li>-- Pelvic inflammatory disease has been reported, with some cases leading to tubal damage, with an increased risk with a sexually transmitted infection, multiple sexual partners, multiple sexual partners who have multiple sexual partners, and a history of pelvic inflammatory disease, which may lead to ectopic pregnancy, infertility, hysterectomy, and death; highest risk within first 20 days after insertion (intrauterine only)<\/li><li>-- Actinomycosis has been reported; if confirmed, remove device and institute antibiotics (intrauterine only)<\/li><li>-- Perforation of the uterus or cervix may occur with insertion of the intrauterine device, with an increased risk in lactating women, in women with fixed retroverted uteri, and during postpartum period; removal required and delay insertion until at least 6 weeks postpartum or until uterine involution is complete (intrauterine only)<\/li><li>-- Partial or complete expulsion may occur; remove if partially expelled and delay insertion until at least 6 weeks postpartum or until uterine involution is complete (intrauterine only)<\/li><li>-- Embedment of the intrauterine device in the myometrium may occur; removal required (intrauterine only)<\/li><li>-- Ovarian cysts may occur; monitoring recommended and surgical intervention may be necessary in some cases (intrauterine only)<\/li><li>-- Menstrual bleeding irregularities may occur; if menses delayed beyond 1 week (oral) or 6 weeks (intrauterine), rule out pregnancy<\/li><li>-- Uterine or cervical malignancy; if arises, removal may be necessary (intrauterine only)<\/li><li>-- Fertility is rapid following use; initiate or continue routine contraception (oral only)<\/li><\/ul>"},{"id":"337200-s-3-11","title":"Pregnancy Category","mono":"X (FDA)<br\/>"},{"id":"337200-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"337200-s-4","title":"Drug Interactions","sub":[{"id":"337200-s-4-13","title":"Contraindicated","mono":"<ul>Tranexamic Acid (probable)<\/ul>"},{"id":"337200-s-4-14","title":"Major","mono":"<ul><li>Aripiprazole (theoretical)<\/li><li>Carbamazepine (probable)<\/li><li>Ceritinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Isotretinoin (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Tizanidine (probable)<\/li><li>Ulipristal (established)<\/li><\/ul>"},{"id":"337200-s-4-15","title":"Moderate","mono":"<ul><li>Acitretin (probable)<\/li><li>Alprazolam (probable)<\/li><li>Amprenavir (probable)<\/li><li>Aprepitant (probable)<\/li><li>Atazanavir (probable)<\/li><li>Bacampicillin (probable)<\/li><li>Betamethasone (probable)<\/li><li>Bexarotene (probable)<\/li><li>Bosentan (probable)<\/li><li>Colesevelam (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Delavirdine (probable)<\/li><li>Eslicarbazepine Acetate (probable)<\/li><li>Etravirine (probable)<\/li><li>Fosamprenavir (established)<\/li><li>Fosaprepitant (probable)<\/li><li>Fosphenytoin (probable)<\/li><li>Griseofulvin (established)<\/li><li>Lamotrigine (established)<\/li><li>Licorice (probable)<\/li><li>Modafinil (probable)<\/li><li>Mycophenolate Mofetil (probable)<\/li><li>Mycophenolic Acid (probable)<\/li><li>Nelfinavir (probable)<\/li><li>Oxcarbazepine (probable)<\/li><li>Perampanel (probable)<\/li><li>Phenobarbital (probable)<\/li><li>Phenytoin (probable)<\/li><li>Prednisolone (established)<\/li><li>Primidone (probable)<\/li><li>Rifabutin (probable)<\/li><li>Rifampin (established)<\/li><li>Rifapentine (probable)<\/li><li>Ritonavir (probable)<\/li><li>Rosuvastatin (probable)<\/li><li>Rufinamide (probable)<\/li><li>Selegiline (probable)<\/li><li>St John's Wort (established)<\/li><li>Tacrine (probable)<\/li><li>Telaprevir (established)<\/li><li>Topiramate (probable)<\/li><li>Troglitazone (probable)<\/li><li>Troleandomycin (established)<\/li><li>Voriconazole (established)<\/li><li>Warfarin (probable)<\/li><\/ul>"}]},"5":{"id":"337200-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Acne (7.2% to 13.6%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (Intrauterine route, 6.8% to 12.8%; oral route, 13.3% to 17.6%), Nausea (Intrauterine route, up to 5.5%; oral route, 13.7% to 23.1%)<\/li><li><b>Neurologic:<\/b>Dizziness (9.6% to 11.2%), Headache (Intrauterine route, 12.4%; oral route, 10.3% to 16.8%)<\/li><li><b>Reproductive:<\/b>Abnormal vaginal bleeding (Mirena(R), 51.9%; Skyla(TM), 59% (first 90 days)), Amenorrhea (Mirena(R), 23.9%; Skyla(TM), up to 12%; Liletta(TM), up to 38%), Breast tenderness (Intrauterine route, 3.3% to 6.7%; oral route, 8.2% to 10.7%), Cyst of ovary (3.4% to 13.2%), Disorder of menstruation (23.4% to 30.9%), Pain in female pelvis (6.1% to 6.2%), Vulvovaginitis (intrauterine system, 13.3% to 20.2%)<\/li><li><b>Other:<\/b>Fatigue (13.3% to 16.7%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Myocardial infarction<\/li><li><b>Hematologic:<\/b>Venous thrombosis<\/li><li><b>Neurologic:<\/b>Thrombotic stroke<\/li><li><b>Psychiatric:<\/b>Suicidal<\/li><li><b>Reproductive:<\/b>Ectopic pregnancy (intrauterine system, 0.1% per year), Pelvic inflammatory disease (0.2 to 0.4%), Uterine perforation by intrauterine contraceptive device (Up to 0.1%)<\/li><li><b>Other:<\/b>Sepsis, Intrauterine device<\/li><\/ul>"},"6":{"id":"337200-s-6","title":"Drug Name Info","sub":{"0":{"id":"337200-s-6-17","title":"US Trade Names","mono":"<ul><li>Plan B<\/li><li>Mirena<\/li><li>Next Choice<\/li><li>Plan B One-Step<\/li><li>Skyla<\/li><li>My Way<\/li><li>Liletta<\/li><\/ul>"},"2":{"id":"337200-s-6-19","title":"Class","mono":"<ul><li>Contraceptive, Local<\/li><li>Contraceptive, Progestin<\/li><li>Progestin<\/li><\/ul>"},"3":{"id":"337200-s-6-20","title":"Regulatory Status","mono":"RX\/OTC<br\/>"},"4":{"id":"337200-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"337200-s-7","title":"Mechanism Of Action","mono":"Levonorgestrel is a synthetic and biologically active progestogen that inhibits ovulation or fertilization via alteration of tubal transport of sperm and\/or ova and thickening the cervical mucus. It also inhibits implantation via alteration of the endometrium.<br\/>"},"8":{"id":"337200-s-8","title":"Pharmacokinetics","sub":[{"id":"337200-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Intrauterine: 2 days<\/li><li>Tmax, Oral: 1.6 to 1.7 hours<\/li><li>Bioavailability, Oral: about 100%<\/li><\/ul>"},{"id":"337200-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 1.8 L\/kg<\/li><li>Protein binding, Sex hormone binding globulin (primarily), albumin (partially): 97.5% to 99%<\/li><\/ul>"},{"id":"337200-s-8-25","title":"Metabolism","mono":"<ul><li>Serum\/Plasma: via conjugation<\/li><li>3-alpha, 5-beta-tetrahydrolevonorgestrel: major<\/li><li>substrate of CYP450 enzymes, especially CYP3A4<\/li><\/ul>"},{"id":"337200-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 32% primarily changed<\/li><li>Renal: 45% changed and unchanged<\/li><li>Total body clearance: 7.7 L\/hr<\/li><\/ul>"},{"id":"337200-s-8-27","title":"Elimination Half Life","mono":"oral, 17 to 27.5 hours <br\/>"}]},"9":{"id":"337200-s-9","title":"Administration","mono":"<ul><li><b>Intrauterine<\/b><br\/>Observe strict asepsis when inserting intrauterine system<br\/><\/li><li><b>Oral<\/b><br\/><ul><li>Take tablet as soon as possible after unprotected intercourse, at any time during the menstrual cycle<\/li><li>Levonorgestrel 0.75 mg (Plan B(R)): if patient vomits within 1 hour of taking either oral dose for post-coital contraception, she should contact her health care professional<\/li><li>Levonorgestrel 1.5 mg (Plan B(R) One-Step): if patient vomits within 2 hours of taking oral dose for post-coital contraception, consideration should be given to repeating the dose<\/li><\/ul><\/li><\/ul>"},"10":{"id":"337200-s-10","title":"Monitoring","mono":"<ul><li>Prevention of pregnancy (eg, negative pregnancy test) is indicative of efficacy<\/li><li>(Liletta(TM)) Re-examine and revaluate patients; 4 to 6 weeks after insertion, once a year thereafter, and more frequently if clinically indicated<\/li><li>(Mirena(R)) Reduction of menstrual bleeding is indicative of efficacy<\/li><li>(Mirena(R)) Blood glucose in patients with diabetes<\/li><li>(Skyla(TM)) Testing for pregnancy and genital or other sexually transmitted infections; prior to insertion<\/li><li>(Skyla(TM)) Endometrial pathology assessment (eg, polyps or cancer); prior to insertion in women with persistent or uncharacteristic bleeding<\/li><li>(Mirena(R)) Physical or pelvic examination; 4 to 12 weeks after insertion and annually thereafter, or more frequently if indicated<\/li><li>(Skyla(TM)) Physical or pelvic examination; 4 to 6 weeks after insertion and annually thereafter, or more frequently if indicated<\/li><\/ul>"},"11":{"id":"337200-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: 0.75 MG, 1.5 MG<br\/><\/li><li><b>EContra EZ<\/b><br\/>Oral Tablet: 1.5 MG<br\/><\/li><li><b>Fallback Solo<\/b><br\/>Oral Tablet: 1.5 MG<br\/><\/li><li><b>Liletta<\/b><br\/>Intrauterine Insert, Extended Release: 52 MG<br\/><\/li><li><b>Mirena<\/b><br\/>Intrauterine Insert, Extended Release: 52 MG<br\/><\/li><li><b>My Way<\/b><br\/>Oral Tablet: 1.5 MG<br\/><\/li><li><b>Next Choice One Dose<\/b><br\/>Oral Tablet: 1.5 MG<br\/><\/li><li><b>Next Choice<\/b><br\/>Oral Tablet: 0.75 MG<br\/><\/li><li><b>Opcicon One-Step<\/b><br\/>Oral Tablet: 1.5 MG<br\/><\/li><li><b>Plan B One-Step<\/b><br\/>Oral Tablet: 1.5 MG<br\/><\/li><li><b>Plan B<\/b><br\/>Oral Tablet: 0.75 MG<br\/><\/li><li><b>Skyla<\/b><br\/>Intrauterine Insert, Extended Release: 13.5 MG<br\/><\/li><\/ul>"},"12":{"id":"337200-s-12","title":"Toxicology","sub":[{"id":"337200-s-12-31","title":"Clinical Effects","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/>USES: To suppress the follicle-stimulating hormone luteinizing hormone sequence from the anterior pituitary, resulting in the suppression of ovulation and production of mucus that is less acceptable to spermatozoa. PHARMACOLOGY: An oral contraceptive acts by suppression of gonadotropins. TOXICOLOGY: There are no significant toxic effects from overdose. OVERDOSE: Abdominal pain, nausea, vomiting, headaches, breast tenderness, dysmenorrhea, arterial thromboembolism, hypertension, venous thrombosis, pulmonary embolus, cerebral thrombosis. ADVERSE EFFECTS: Nausea and vomiting with iron containing contraceptives in children, otherwise asymptomatic. <br\/>"},{"id":"337200-s-12-32","title":"Treatment","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: The vast majority of oral contraceptive overdoses require only supportive care. MANAGEMENT OF SEVERE TOXICITY: Severe toxicity is not expected in single substance oral contraceptive ingestion.<\/li><li>Decontamination: There is no need for GI decontamination.<\/li><li>Airway management: Patients with single substance oral contraceptive ingestion will not require airway management.<\/li><li>Antidote: None.<\/li><li>Enhanced elimination procedure: Hemodialysis and hemoperfusion are not of value.<\/li><li>Monitoring of patient: Concentrations of the hormones in oral contraceptives are not clinically useful. No routine laboratory studies are needed in most patients.<\/li><li>Patient disposition: HOME CRITERIA: Patients with inadvertent ingestions can be managed at home. If oral contraceptives containing iron are ingested, asymptomatic patients ingesting less than 40 mg\/kg elemental iron can be managed at home. OBSERVATION CRITERIA: The following patients should be sent to a healthcare facility for evaluation: Patients with self-harm ingestions; patients ingesting iron-containing oral contraceptives at a dose of more than 40 mg\/kg elemental iron or who have symptoms (nausea, vomiting, or other gastrointestinal complaints). ADMISSION CRITERIA: Patients with pure oral contraceptive overdoses do not need admission. Children with exposure to iron-containing products should follow the iron guidelines for admission. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients for any additional questions.<\/li><\/ul>"},{"id":"337200-s-12-33","title":"Range of Toxicity","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/>TOXICITY: A human toxic dose has not been established. Significant toxicity has not been reported after overdose. THERAPEUTIC DOSE: Oral contraceptives are available in various brands, doses, and formulations. <br\/>"}]},"13":{"id":"337200-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to practice safe sex. Drug does not prevent disease transmission.<\/li><li>Tell patient using an intrauterine device to report symptoms of infection (including STD or HIV), new or worsening headaches, symptoms of hepatotoxicity, or severe arterial disease (eg, myocardial infarction or stroke).<\/li><li>Instruct patient to consult healthcare professional if pregnancy occurs with intrauterine device use.<\/li><li>Intrauterine device may cause ovarian cyst, acne or seborrhea, abdominal or pelvic pain, vulvovaginitis, or changes in bleeding patterns.<\/li><li>This drug may cause acne, weight gain, abdominal pain, nausea, dizziness, headache, depression, breast tenderness, dysmenorrhea, or fatigue.<\/li><li>Tell patient using an intrauterine device to report persistent\/recurrent abnormal vaginal bleeding  or amenorrhea lasting 6 weeks or more.<\/li><li>Patient using an intrauterine device should report signs\/symptoms of pelvic inflammatory disease (abdominal pain, fever, abnormal vaginal discharge, vomiting, painful intercourse or urination).<\/li><li>Instruct patient to seek medical attention if severe lower abdominal pain occurs 3 to 5 weeks after oral emergency contraception use, to evaluate for ectopic pregnancy.<\/li><li>Consider pregnancy if menstruation is delayed more than one week of anticipated date when product is used orally for emergency contraception.<\/li><li>Counsel patient using an intrauterine device to check threads monthly and report expulsion as contraceptive efficacy may be lost.<\/li><li>Tell patient that intrauterine device must be removed or replaced after 3 years.<\/li><li>Advise patient to take emergency contraception dose as soon as possible to maximize effectiveness, and within 72 hours after unprotected intercourse or contraception failure.<\/li><li>Advise patient that there are multiple and significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the-counter and herbal drugs, such as St. John's wort).<\/li><li>Direct patient to inform healthcare providers of intrauterine device use before any MRI scan.<\/li><li>When used for emergent, postcoital contraception, advise patient to contact healthcare professional if vomiting occurs within 2 hours of taking either oral dose.<\/li><\/ul>"}}}